Skip to main content
Year archive

Lee's Pharmaceutical Holdings Limited — 2022 filings

All 50 regulatory filings released by Lee's Pharmaceutical Holdings Limited (950) in 2022, sourced directly from the official regulator.

50 Filings
2022 Period
2022 filings (50)
Filing Released Lang
Terms of Reference of the Remuneration Committee
Remuneration Information
2022-12-16 English
Grant of Share Options
Share Issue/Capital Change
2022-12-02 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2022
Regulatory Filings
2022-12-01 English
Third Quarterly Report 2022
Interim / Quarterly Report 9M 2022
2022-11-24 English
Third Quarterly Results Announcement for the Nine Months Ended 30 September 2022
Interim / Quarterly Report 9M 2022
2022-11-17 English
Voluntary Announcement - Approval of a Drug Product Manufactured by Zhaoke Guangzhou to Conduct Clinical Trial in the United States
Regulatory Filings
2022-11-09 English
Notice of Board Meeting
Regulatory Filings
2022-11-04 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2022
Share Issue/Capital Change
2022-11-01 English
Voluntary Announcement - Completion of Patient Enrolment for a Phase III Clinical Trial of Intrarosa
Regulatory Filings
2022-10-26 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2022
Regulatory Filings
2022-10-03 English
Voluntary Announcement - Obtaining Drug Marketing Authorisation of Azilsartan Tablets
Regulatory Filings
2022-09-29 English
Discloseable Transaction - Disposal of Equity Interest in a Subsidiary
Capital/Financing Update
2022-09-22 English
Interim Report 2022
Interim / Quarterly Report H1 2022
2022-09-19 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2022
Share Issue/Capital Change
2022-09-01 English
Interim Dividend for the Six Months Ended 30 June 2022
Notice of Dividend Amount
2022-08-26 English
Interim Results for the Six Months Ended 30 June 2022
Interim / Quarterly Report H1 2022
2022-08-26 English
Voluntary Announcement - Obtains Global License of SURFAXIN, SURFAXIN LS and AEROSURF from Windtree Therapeutics, Inc.
Capital/Financing Update
2022-08-23 English
Notice of Board Meeting
Regulatory Filings
2022-08-16 English
Profit Warning
Regulatory Filings
2022-08-15 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2022
Regulatory Filings
2022-08-01 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2022
Regulatory Filings
2022-07-04 English
Voluntary Announcement - Teglutik Obtains Drug Registration Certificate
Regulatory Filings
2022-06-21 English
First Quarterly Report 2022
Interim / Quarterly Report Q1 2022
2022-06-01 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2022
Share Issue/Capital Change
2022-06-01 English
Environmental, Social and Governance Report 2021
Environmental & Social Information
2022-05-30 English
First Quarterly Results Announcement for the Three Months Ended 31 March 2022
Interim / Quarterly Report Q1 2022
2022-05-26 English
Supplemental Announcement in relation to the Poll Results of Annual General Meeting held on 19 May 2022
Declaration of Voting Results & Voting Rights Announcements
2022-05-20 English
Voluntary Announcement - Natulan Obtains Drug Registration Certificate
Regulatory Filings
2022-05-19 English
Annual General Meeting Held on 19 May 2022 - Poll Results
Declaration of Voting Results & Voting Rights Announcements
2022-05-19 English
Notice of Board Meeting
Regulatory Filings
2022-05-16 English
Voluntary Announcement - Update on an Investigational Oncology Drug Product
Regulatory Filings
2022-05-13 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2022
Regulatory Filings
2022-05-04 English
Grant of Share Options
Director's Dealing
2022-04-25 English
Share Option Scheme
Regulatory Filings
2022-04-21 English
Proxy Form
Proxy Solicitation & Information Statement
2022-04-21 English
Notice of Annual General Meeting
AGM Information
2022-04-21 English
General Mandates to Repurchase Shares and to Issue New Shares, Re-election of Directors, Adoption of New Share Option Scheme, Adoption of Amended and Restated Memorandum and Articles of Association an
AGM Information
2022-04-21 English
Annual Report 2021
Annual Report FY 2021
2022-04-21 English
Voluntary Announcement - INOmax obtains Drug Registration Certificate
Regulatory Filings
2022-04-21 English
Proposed Adoption of New Share Option Scheme and Proposed Adoption of Amended and Restated Memorandum and Articles of Association
Regulatory Filings
2022-04-06 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2022
Share Issue/Capital Change
2022-04-01 English
Final Dividend for the year ended 31 December 2021
Notice of Dividend Amount
2022-03-29 English
Announcement of Annual Results for the year ended 31 December 2021
Annual Report FY 2021
2022-03-29 English
Notice of Board Meeting
Regulatory Filings
2022-03-17 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2022
Share Issue/Capital Change
2022-03-01 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2022
Share Issue/Capital Change
2022-02-04 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2021
Share Issue/Capital Change
2022-01-04 English
List of Directors and their Roles and Functions
Board/Management Information
2022-01-02 English
Terms of Reference of the Nomination Committee
Governance Information
2022-01-02 English
Appointment of Non-executive Director and Establishment of Nomination Committee
Board/Management Information
2022-01-02 English